Skip to main content

ETHNOS_APP

Home • Search • Journals • List 0

Xiaohui Zeng

Biographic Data

ID7303415
NAMEXiaohui Zeng
GIVEN NAMESXiaohui
FAMILY NAMEZeng
SIGNATUREZENG X
AFFILIATIONSCentral South University
ORCID0000-0002-4259-4658
VERIFIEDYes
TOTAL WORKS7
TOTAL CITATIONS0
AUTHOR COUNT7
EDITOR COUNT0
FIRST PUBLICATION YEAR2020
LATEST PUBLICATION YEAR2026
H-INDEX0
  • Modified Suoquan Wan ameliorate bladder overactivity via Piezo1/Mapk/MLC axis in partial bladder outlet obstruction rats

    Open Access•Hui Li, Hongliang Li et al.•ARTICLE•Journal of Ethnopharmacology•2026

  • Impact of transaction-oriented financial assets on firm innovation in China

    Open Access•Wenjing Yu, Qilin Zhan et al.•ARTICLE•Humanities and Social Sciences…•2025

    This study examines the impact of transaction-oriented financial assets on firm innovation using data from non-financial listed firms in China’s A-share market from 2008–2019. These findings suggest that transaction-oriented financial assets promote innovation. Specifically, such an allocation mitigates the influence of external financing constraints on firms by providing continuous financial support for innovation activities, thereby demonstrati…

  • Cost-effectiveness analysis of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer

    Open Access•Juan Hong, Xiaohui Zeng et al.•ARTICLE•Frontiers in Public Health•2025

    Objectives: Rezvilutamide, an androgen-receptor inhibitor, has been approved by the Chinese National Medical Products Administration as a first-line treatment for high-volume metastatic hormone-sensitive prostate cancer (mHSPC). This study aims to assess the cost-effectiveness of rezvilutamide plus androgen-deprivation therapy (ADT) compared to bicalutamide plus ADT for the first-line treatment of high-volume mHSPC in China. Methods: A Markov mod…

  • Lung cancer screening with low-dose computed tomography

    Open Access•Xiaohui Zeng, Zhen Zhou et al.•ARTICLE•Frontiers in Public Health•2022

    Objective: To compare the cost-effectiveness of undertaking low-dose computed tomography (LDCT) screening for early detection of lung cancer (LC) with different frequencies within the healthcare system of China, and estimate the additional national healthcare expenditure and five-year LC mortality associated with different screening frequencies. Material and methods: A Markov model was established using national LC epidemiological data from the C…

  • Benefit-to-harm ratio and cost-effectiveness of government-recommended gastric cancer screening in China

    Open Access•Shuxia Qin, Xuehong Wang et al.•ARTICLE•Frontiers in Public Health•2022

    Objective: Current guidelines recommend the gastric cancer risk score scale (GCRSS) for screening in gastric cancer (GC) high-risk populations in China. This study aimed to estimate the clinical benefits, harms, cost, and cost-effectiveness of the GCRSS screening strategy from a Chinese healthcare system perspective. Materials and methods: Using a microsimulation model, we evaluated 7 screening scenarios of the GCRSS with varying starting ages. W…

  • Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China

    Open Access•Xia Luo, Zhen Zhou et al.•ARTICLE•Frontiers in Public Health•2022

    Objective Six anaplastic lymphoma kinase-tyrosine kinase inhibitors (ALK-TKIs), including one domestic (ensartinib) and five imported ALK-TKIs (crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib), have been recommended as first-line treatments for advanced ALK-positive NSCLC in China. This study sought to examine the cost-effectiveness of these six novel therapies in Chinese patients. Material and methods We constructed a Markov model t…

  • The influence of minimum wage regulation on labor income share and overwork

    Open Access•Qilin Zhan, Xiaohui Zeng et al.•ARTICLE•Economic Research-Ekonomska…•2020

    Minimum Wage Regulation (MWR) can raise wage rate, but its relation with labor income share is in controversy. We explore the influence of raising wage rate on labor income share and overwork in China. Panel data regressions are taken mainly based on China’s Industrial Enterprise Database and the International Labor Organization Database. Our findings show that raising wage rate can increase labor income share without leading to overwork. Factors…

No prominent works on this page.

  • The influence of minimum wage regulation on labor income share and overwork

    Open Access•Qilin Zhan, Xiaohui Zeng et al.•ARTICLE•Economic Research-Ekonomska…•2020

    Minimum Wage Regulation (MWR) can raise wage rate, but its relation with labor income share is in controversy. We explore the influence of raising wage rate on labor income share and overwork in China. Panel data regressions are taken mainly based on China’s Industrial Enterprise Database and the International Labor Organization Database. Our findings show that raising wage rate can increase labor income share without leading to overwork. Factors…

  • Lung cancer screening with low-dose computed tomography

    Open Access•Xiaohui Zeng, Zhen Zhou et al.•ARTICLE•Frontiers in Public Health•2022

    Objective: To compare the cost-effectiveness of undertaking low-dose computed tomography (LDCT) screening for early detection of lung cancer (LC) with different frequencies within the healthcare system of China, and estimate the additional national healthcare expenditure and five-year LC mortality associated with different screening frequencies. Material and methods: A Markov model was established using national LC epidemiological data from the C…

  • Benefit-to-harm ratio and cost-effectiveness of government-recommended gastric cancer screening in China

    Open Access•Shuxia Qin, Xuehong Wang et al.•ARTICLE•Frontiers in Public Health•2022

    Objective: Current guidelines recommend the gastric cancer risk score scale (GCRSS) for screening in gastric cancer (GC) high-risk populations in China. This study aimed to estimate the clinical benefits, harms, cost, and cost-effectiveness of the GCRSS screening strategy from a Chinese healthcare system perspective. Materials and methods: Using a microsimulation model, we evaluated 7 screening scenarios of the GCRSS with varying starting ages. W…

  • Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China

    Open Access•Xia Luo, Zhen Zhou et al.•ARTICLE•Frontiers in Public Health•2022

    Objective Six anaplastic lymphoma kinase-tyrosine kinase inhibitors (ALK-TKIs), including one domestic (ensartinib) and five imported ALK-TKIs (crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib), have been recommended as first-line treatments for advanced ALK-positive NSCLC in China. This study sought to examine the cost-effectiveness of these six novel therapies in Chinese patients. Material and methods We constructed a Markov model t…

  • Impact of transaction-oriented financial assets on firm innovation in China

    Open Access•Wenjing Yu, Qilin Zhan et al.•ARTICLE•Humanities and Social Sciences…•2025

    This study examines the impact of transaction-oriented financial assets on firm innovation using data from non-financial listed firms in China’s A-share market from 2008–2019. These findings suggest that transaction-oriented financial assets promote innovation. Specifically, such an allocation mitigates the influence of external financing constraints on firms by providing continuous financial support for innovation activities, thereby demonstrati…

  • Cost-effectiveness analysis of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer

    Open Access•Juan Hong, Xiaohui Zeng et al.•ARTICLE•Frontiers in Public Health•2025

    Objectives: Rezvilutamide, an androgen-receptor inhibitor, has been approved by the Chinese National Medical Products Administration as a first-line treatment for high-volume metastatic hormone-sensitive prostate cancer (mHSPC). This study aims to assess the cost-effectiveness of rezvilutamide plus androgen-deprivation therapy (ADT) compared to bicalutamide plus ADT for the first-line treatment of high-volume mHSPC in China. Methods: A Markov mod…

  • Modified Suoquan Wan ameliorate bladder overactivity via Piezo1/Mapk/MLC axis in partial bladder outlet obstruction rats

    Open Access•Hui Li, Hongliang Li et al.•ARTICLE•Journal of Ethnopharmacology•2026

Internal Medicine (4 works) · Medicine (4 works) · China (3 works) · Cancer (2 works) · Economic and Financial Impacts of Cancer (2 works) · Lung cancer (2 works) · Lung Cancer Treatments and Mutations (2 works) · Oncology (2 works) · Alectinib (1 works) · ALK inhibitor (1 works)

Ethnos_APP • Open Source Project • MIT License • Frontend v2.0.0 • Privacy and Cookies • API Documentation: api.ethnos.app/docs • API Source Code: GitHub • DOI: 10.5281/zenodo.17049435 • Frontend Source Code: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae